C300-010
Recombinant Vesicular Stomatitis Virus pseudotyped SARS-CoV-2 Variant of Concern (VOCs) Panel
$ 3,500
Size:

8 vials

Quantity:

1

Description

The recombinant Vesicular Stomatitis Virus (rVSV-ΔG) reverse genetics pseudotype system is widely used to generate rVSV particles that express the surface glycoprotein protein of a heterologous virus. This is a particularly powerful tool to study viruses that require high level biosafety containment (BSL-3 and BSL-4) such as Coronaviruses and Filoviruses1,2, as it generates virus that is restricted to a single round of replication, making them BSL-2 level compatible. 

Individual rVSV-SARS-CoV-2 variants can be found here:

rVSV-SARS-CoV-2 (D614G)

rVSV-SARS-CoV-2 (Alpha)

rVSV-SARS-CoV-2 (Beta)

rVSV-SARS-CoV-2 (Gamma)

rVSV-SARS-CoV-2 (Delta)

rVSV-SARS-CoV-2 (Epsilon)

rVSV-SARS-CoV-2 (Omicron)

Product Type: Virus

Serotype: VSV Indiana / SARS-CoV-2 (MN908947), SARS-CoV-2 (D614G), SARS-CoV-2 (Alpha), SARS-CoV-2 (Beta), SARS-CoV-2 (Delta), SARS-CoV-2 (Gamma), SARS-CoV-2 (Epsilon), SARS-CoV-2 (Omicron)

Synonyms: SARS-CoV-2 virus, SARS-CoV-2-VSV, SARS-CoV-2 virus, SARS-CoV-2 pseudotype, rVSV-SARS-CoV-2, COVID-19 virus, COVID-19 pseudovirus, COVID-19 pseudotype, 2019-nCoV, 2019-nCoV pseudotype virus

Biosafety Level: BSL-2

Applications: Screening antibodies or drugs for anti-SARS-CoV-2 neutralization activity, monitoring SARS-CoV-2 entry into target cells. Comparing the potency of different antiviral compounds to neutralize SARS-CoV-2 variants.

Store: -80C. Multiple freeze thaw cycles will reduce titer.

Shipped: Dry Ice

Titer:  Will be supplied with packing list

Size: A single vial can be used for 96 x 8 reactions. Please contact services@eliteimmune.com for protocol.

Intended Use: This product is for research use only. It is not intended for human, therapeutic, or diagnostic use. Buyer may not modify, sell, or transfer product for commercial use without written permission from Eliteimmune.

References:

1.Howell, K.A., et al., Cooperativity Enables Non-Neutralizing Antibodies to Neutralize Ebolavirus. Cell Reports, 2017. 19(2): p. 413-424.

2.Whitt, M.A., Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods, 2010. 169(2): p. 365-74.

Alternative Names:

Related Products